Publications

This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.

This article demonstrates MyoStrain’s speed and sensitivity to successfully measure cardiac stress during a safe, simple hyperventilation breathing maneuver. Performed without any pharmacological or physical stress protocols, this new technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease.

The study compared MyoStrain’s ability to quantify and differentiate asymptomatic patients based on their cardiac risk versus traditional ejection faction, reiterating the technology's potential as a critical cardiac risk stratification tool enabling clinicians to identify at-risk patients early for individualized preventative treatment.

This article demonstrates MyoStrain's ability to identify patients with subclinical LV dysfunction and those at risk for heart failure-related outcomes compared with LVEF, providing an additional diagnostic window for prevention treatments.

A cost-impact analysis of MyoStrain in the early diagnosis and management of MyoStrain, this manuscript compares the cost-saving potential of MyoStrain versus echocardiography.

This clinical review article describes the history and evolution of the MyoStrain technology. The manuscript itself provides a detailed summary of existing literature about MyoStrain and its predecessor technologies HARP and SENC, totaling 400+ publications representing 70,000+ patient data points to date.